Sunshine Biopharma Inc., operating under the industrial classification of pharmaceutical preparations, has been known previously by different names, including Mountain West Business Solutions, Inc., before settling on its current name. The company's headquarters are located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
The election saw the company's stockholders vote in favor of retaining the current board of directors, including Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller. The directors will serve until the next annual meeting or until their successors are duly elected and qualified. The detailed vote count showed overwhelming support for each director, with Dr. Steve N. Slilaty receiving the highest number of votes at 130,067,932 for and 48,554 withheld.
Additionally, the stockholders ratified the appointment of Bush & Associates CPA LLC as Sunshine Biopharma's independent registered public accounting firm for the upcoming fiscal year. The decision was made with a significant majority, with 130,089,305 votes for, 15,456 against, and 11,725 abstentions.
Sunshine Biopharma Inc., operating under the industrial classification of pharmaceutical preparations, has been known previously by different names, including Mountain West Business Solutions, Inc., before settling on its current name. The company's headquarters are located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
While the company holds more cash than debt on its balance sheet, InvestingPro's Fair Value analysis suggests the stock may be currently undervalued, presenting a potential opportunity for investors willing to navigate the company's recent stock price volatility.
Sunshine Biopharma Inc., operating under the industrial classification of pharmaceutical preparations, has been known previously by different names, including Mountain West Business Solutions, Inc., before settling on its current name. The company's headquarters are located at 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.
In other recent news, Sunshine Biopharma has made significant strides in its operations. The pharmaceutical company has launched a new generic liver drug, Ursodiol, through its Canadian subsidiary, Nora Pharma Inc., expanding its footprint in the Canadian generic drugs market. The Ursodiol market, currently valued at approximately $457.9 million, is projected to reach around $933.9 million by 2029.
Furthermore, Sunshine Biopharma has expanded its generic drug portfolio with the introduction of two new generic prescription drugs, Varenicline and Betahistine. This growth has increased the number of products in Nora Pharma's portfolio to 63. The company also plans to launch 31 additional drugs by the end of 2025.
Sunshine Biopharma has also regained compliance with Nasdaq's minimum bid price requirement. This was achieved by executing a strategic 1-for-20 reverse stock split, consolidating every twenty shares of issued and outstanding common stock into a single share. The company also announced the full exercise of all Series A Warrants issued in 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.